Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2022 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer

DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
February 10, 2022 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present at the SVB Leerink Global Healthcare Conference

DEVON, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
January 06, 2022 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

DEVON, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
January 04, 2022 16:05 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

– Company plans to focus development of Zygel™ in FXS, ASD and 22q – – Company plans to initiate Phase 3 trial with Zygel in ASD in the second half of 2022 – – Zynerba to hold conference call...
December 06, 2021 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium

DEVON, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
November 22, 2021 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™

DEVON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
November 15, 2021 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights

– Initiated RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X Syndrome (FXS); topline results expected second-half 2023 – – Cash runway well into the first half of...
October 21, 2021 07:00 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October

DEVON, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
October 19, 2021 16:15 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

DEVON, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
October 08, 2021 07:30 ET | Source: Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition

DEVON, Pa., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...